Fang Zhang

Fang Zhang has extensive work experience in the biotechnology and pharmaceutical industries. Starting in 2001, Fang worked as a Research Scientist at DNA Sciences, Inc. and later joined Metabolex, Inc. as a Research Scientist I-III in 2002. In 2007, Fang joined Eli Lilly and Company as a Senior Research Scientist and remained with the company until 2012.

From 2012 to 2020, Fang Zhang held various roles at Novo Nordisk, including Department Head of Diabetes Biology, Department Head of Diabetes Biology and Pharmacology, Director and Senior Director of Diabetes Biology and Pharmacology, and Vice President of Discovery Biology and Head of Diabetes Research in China.

In 2020, Fang became the Chief Executive Officer of Shanghai Tuojie Biomedical Technology. In 2021, Fang Zhang transitioned to the role of Senior Vice President of Biology at Structure Therapeutics and later became the Executive Vice President of Biology in 2022.

Fang Zhang completed a Bachelor of Science degree in Biological Sciences and Biotechnology at Tsinghua University from 1992 to 1997. Subsequently, Zhang pursued a Ph.D. in Oncological Sciences at the University of Utah between 1997 and 2001.